Neil Cataldi from Blueprint on Sanara Medtech $SMTI
About this episode
Neil Cataldi from Blueprint Capital discusses his investment thesis for Sanara Medtech (SMTI). Sanara is growing quickly, and Neil thinks continued growth in their product portfolio and hospitals they are approved to sell in will drive continued accelerated growth and long term compounding.
Chapters
0:00 Intro
1:00 Sanara overview
5:30 How is Sanara increasing their hospital reach?
14:25 Discussing management
21:10 Related party risks
33:20 Breaking down SMTI's growth
42:45 Sanara's telehealth ambitions
1:01:10 Closing thoughts
Get every episode summarized
Each time Yet Another Value Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Yet Another Value Podcast
UK stocks are dirt cheap. Why won't the boards act? $ZIG $CRW | Undervalued-Shar...
Yet Another Value Podcast
Zack Buckley on $PRTH's take private
Yet Another Value Podcast
$TBBB: Tiendas 3B is Mexico's Aldi. Is it too late to buy? | Fruit Tree Capital
Yet Another Value Podcast
$LMB: Limbach missed the data center boom. Is that the opportunity? | 1 Main Cap...
Yet Another Value Podcast